Ποια είναι η τιμή για AP Biosciences Inc (6945)

Η τιμή για AP Biosciences Inc (6945) είναι $3.06

Ποια είναι η κεφαλαιοποίηση αγοράς για AP Biosciences Inc (6945)

Η κεφαλαιοποίηση αγοράς για AP Biosciences Inc (6945) είναι $296.40M

AP Biosciences Inc (6945) Διαίρεση Μετοχών

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.